{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:09Z","timestamp":1791580809687,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106798","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:49:07Z","timestamp":1760546947000},"page":"106798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Rituximab regimens and lymphocyte counts in patients with neuromyelitis optica: A systematic review"],"prefix":"10.1016","volume":"104","author":[{"given":"Paola Andrea","family":"Ortiz-Salas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alejandra","family":"Quilaguy-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Sebastian","family":"Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"G\u00f3mez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Pineda-Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106798_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103926","article-title":"Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: a systematic review","volume":"63","author":"Abbadessa","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1166490","article-title":"Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: a systematic review and network meta-analysis","volume":"14","author":"Aungsumart","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0004","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106798_bib0035","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106798_bib0028","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104524","article-title":"B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: a real-world case series study","volume":"70","author":"Cao","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3390\/jcm13020355","article-title":"Relapses and serious infections in patients with Neuromyelitis Optica spectrum disorder treated with Rituximab: a Swedish single-center study","volume":"13","author":"Carlsson","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2025.106798_bib0036","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cca.2014.11.004","article-title":"Biomarkers for neuromyelitis optica","volume":"440","author":"Chang","year":"2015","journal-title":"Clinica. Chimica. Acta"},{"key":"10.1016\/j.msard.2025.106798_bib0024","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jns.2017.01.025","article-title":"Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: results from a bicentric study","volume":"373","author":"Cohen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106798_bib0017","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106798_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105600","article-title":"FCGR3A-V158F gene polymorphism: a potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder","volume":"86","author":"Cui","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1513303","article-title":"The monitoring of B lymphocytes in non-lymphoma patients following rituximab treatment","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106798_bib0040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to Rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00415-018-9092-4","article-title":"Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica\/neuromyelitis optica spectrum disorders","volume":"266","author":"Ellrichmann","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","article-title":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","volume":"372","author":"Evangelopoulos","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106798_bib0011","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-022-00709-4","article-title":"Neuromyelitis optica spectrum disorders (NMOSD)","volume":"24","author":"Glisson","year":"2022","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106798_bib0019","doi-asserted-by":"crossref","unstructured":"Greenberg B.M., Graves D., Remington G., Hardeman P., Mann M., Karandikar N., Stuve O., Monson N., Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. http:\/\/dx.doi.org\/101177\/1352458511432896 [Internet]. 2012 [cited 2025 Feb 17];18:1022\u20131026. doi: 10.1177\/1352458511432896. Cited: in:: PMID: 22261118.","DOI":"10.1177\/1352458511432896"},{"key":"10.1016\/j.msard.2025.106798_bib0009","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0003","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with Rituximab in 100 patients with neuromyelitis Optica: influence of FCGR3A polymorphisms on the therapeutic response to Rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor Rituximab administration to patients with Neuromyelitis Optica spectrum disorders","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106798_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101933","article-title":"A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders","volume":"40","author":"Lu","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101430","article-title":"Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders","volume":"36","author":"Novi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0018","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106798_bib0023","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106798_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104563","article-title":"2 grams versus 1 gram rituximab as maintenance schedule in multiple sclerosis, neuromyelitis optica spectrum disorders and related diseases: what B-cell repopulation data tell us","volume":"71","author":"Rual","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0007","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of anti-B cell therapeutics in autoimmune neurological diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106798_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1130971","article-title":"New advancements in the management of Neuromyelitis Optica spectrum disease: literature review","volume":"3","author":"Sudhakar","year":"2023","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.msard.2025.106798_bib0013","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): b cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0042","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2015.1421","article-title":"Rituximab therapy in Neuromyelitis Optica: moving toward a personalized medicine approach","volume":"72","author":"Tobin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0006","first-page":"43","article-title":"Precision therapy for neuromyelitis optica spectrum disorder: a retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules","author":"Trewin","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000317","article-title":"Aquaporin-4 antibody titration in NMO patients treated with rituximab: a retrospective study","volume":"4","author":"Valentino","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106798_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0038","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5316\/wjn.v5.i1.39","article-title":"Rituximab in neuromyelitis optica: a review of literature","volume":"5","author":"Wong","year":"2015","journal-title":"World J. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0037","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106798_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00642","article-title":"Retrospective observation of low-dose rituximab treatment in Chinese patients with Neuromyelitis Optica spectrum disorders in a real-world setting","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106798_bib0021","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106798_bib0029","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106798_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578285","article-title":"Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder","volume":"387","author":"Zhang","year":"2024","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825005401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:32:50Z","timestamp":1784345570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825005401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"alternative-id":["S2211034825005401"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106798","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab regimens and lymphocyte counts in patients with neuromyelitis optica: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106798"}}